Roflumilast: a review of its use in the treatment of COPD

References

• AgustiAGCOPD, a multicomponent disease: implications for managementRespir Med200599667068215878483
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease2014 Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jan23.pdfAccessed July 28, 2015
   Google Scholar
• GanWQManSFSenthilselvanASinDDAssociation between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysisThorax200459757458015223864
   PubMed Web of Science ®Google Scholar
• FabbriLMRabeKFFrom COPD to chronic systemic inflammatory syndrome?Lancet2007370958979779917765529
   PubMed Web of Science ®Google Scholar
• HoggJCChuFUtokaparchSThe nature of small-airway obstruction in chronic obstructive pulmonary diseaseN Engl J Med2004350262645265315215480
   PubMed Web of Science ®Google Scholar
• SaettaMAirway inflammation in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19991605 Pt 2S17S2010556163
   PubMed Web of Science ®Google Scholar
• DonaldsonGCHurstJRSmithCJHubbardRBWedzichaJAIncreased risk of myocardial infarction and stroke following exacerbation of COPDChest201013751091109720022970
   PubMed Web of Science ®Google Scholar
• FearyJRRodriguesLCSmithCJHubbardRBGibsonJEPrevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary careThorax2010651195696220871122
   PubMed Web of Science ®Google Scholar
• StällbergBJansonCJohanssonGManagement, morbidity and mortality of COPD during an 11-year period: an observational retrospective epidemiological register study in Sweden (PATHOS)Prim Care Respir J2014231384524346825
   PubMedGoogle Scholar
• WedzichaJABrillSEAllinsonJPDonaldsonGCMechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary diseaseBMC Med20131118123945277
   PubMed Web of Science ®Google Scholar
• PeacockJLAndersonHRBremnerSAOutdoor air pollution and respiratory health in patients with COPDThorax201166759159621459856
   PubMed Web of Science ®Google Scholar
• SethiSMurphyTFInfection in the pathogenesis and course of chronic obstructive pulmonary diseaseN Engl J Med2008359222355236519038881
   PubMed Web of Science ®Google Scholar
• BathoornELieskerJJPostmaDSChange in inflammation in outpatient COPD patients from stable phase to a subsequent exacerbationInt J Chron Obstruct Pulmon Dis2009410110919436694
   PubMedGoogle Scholar
• HurstJRDonaldsonGCPereraWRUse of plasma biomarkers at exacerbation of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2006174886787416799074
   PubMed Web of Science ®Google Scholar
• MalliaPMessageSDGielenVExperimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbationAm J Respir Crit Care Med2010183673474220889904
   PubMed Web of Science ®Google Scholar
• TkacovaRKluchovaZJoppaPPetrasovaDMolcanyiovaASystemic inflammation and systemic oxidative stress in patients with acute exacerbations of COPDRespir Med200710181670167617449234
   PubMed Web of Science ®Google Scholar
• SeemungalTADonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981575 Pt 1141814229603117
   PubMed Web of Science ®Google Scholar
• SeneffMGWagnerDPWagnerRPZimmermanJEKnausWAHospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary diseaseJAMA199527423185218577500534
   PubMed Web of Science ®Google Scholar
• Soler-CatalunaJJMartinez-GarciaMARoman SanchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
   PubMed Web of Science ®Google Scholar
• SuissaSDell’AnielloSErnstPLong-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortalityThorax2012671195796322684094
   PubMed Web of Science ®Google Scholar
• American Thoracic Society/European Respiratory SocietyStandards for the diagnosis and management of patients with COPD2004 Available from: http://www.thoracic.org/copd-guidelines/resources/copddoc.pdfAccessed January 23, 2015
   Google Scholar
• QaseemAWiltTJWeinbergerSEDiagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory SocietyAnn Intern Med2011155317919121810710
   PubMed Web of Science ®Google Scholar
• Daliresp (roflumilast) tablets [package insert]Wilmington, DEAstra-Zeneca Pharmaceuticals LP2015
   Google Scholar
• HatzelmannAMorcilloEJLungarellaGThe preclinical pharmacology of roflumilast – a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary diseasePulm Pharmacol Ther201023423525620381629
   PubMed Web of Science ®Google Scholar
• SanzMJCortijoJMorcilloEJPDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expressionPharmacol Ther2005106326929715922015
   PubMed Web of Science ®Google Scholar
• GrootendorstDCGauwSAVerhooselRMReduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPDThorax200762121081108717573446
   PubMed Web of Science ®Google Scholar
• GauvreauGMBouletLPSchmid-WirlitschCRoflumilast attenuates allergen-induced inflammation in mild asthmatic subjectsRespir Res20111214022029856
   PubMed Web of Science ®Google Scholar
• SchickMAWunderCWollbornJPhosphodiesterase-4 inhibition as a therapeutic approach to treat capillary leakage in systemic inflammationJ Physiol2012590Pt 112693270822495586
   PubMed Web of Science ®Google Scholar
• HermannRNassrNLahuGSteady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosisClin Pharmacokinet200746540341617465639
   PubMed Web of Science ®Google Scholar
• WestphalJFMacrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focuses on clarithromycin, azithromycin and dirithromycinBr J Clin Pharmacol200050428529511012550
   PubMed Web of Science ®Google Scholar
• CalverleyPMRabeKFGoehringUMKristiansenSFabbriLMMartinezFJRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsLancet2009374969168569419716960
   PubMed Web of Science ®Google Scholar
• FabbriLMCalverleyPMIzquierdo-AlonsoJLRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long-acting bronchodilators: two randomised clinical trialsLancet2009374969169570319716961
   PubMed Web of Science ®Google Scholar
• RabeKFBatemanEDO’DonnellDWitteSBredenbrökerDBethkeTDRoflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trialLancet2005366948556357116099292
   PubMed Web of Science ®Google Scholar
• RennardSICalverleyPMGoehringUMBredenbrökerDMartinezFJReduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPDRespir Res2011121821272339
   PubMed Web of Science ®Google Scholar
• MartinezFJCalverleyPMAGoehringUMBroseMFabbriLMRabeKFEffect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trialLancet2015385997185786625684586
   PubMed Web of Science ®Google Scholar
• ZhengJYangJZhouXRoflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group studyChest20141451445224135893
   PubMed Web of Science ®Google Scholar
• RabeKFUpdate on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary diseaseBr J Pharmacol20111631536721232047
   PubMed Web of Science ®Google Scholar
• BatemanEDRabeKFCalverleyPMRoflumilast with long-acting β2-agonists for COPD: influence of exacerbation historyEur Respir J201138355356021737553
   PubMed Web of Science ®Google Scholar
• WedzichaJARabeKFMartinezFJEfficacy of roflumilast in the COPD frequent exacerbator phenotypeChest201314351302131123117188
   PubMed Web of Science ®Google Scholar
• BatemanEDJardimJGoehringUMBroseMCalverlyPEffect of roflumilast on hospitalizations in COPD patientsEur Resp J201240Suppl 56P2109
   Google Scholar
• FabbriLGoehringUMBroseMRabeKEffects of roflumilast in highly symptomatic COPD patientsEur Resp J201240Suppl 56P742
   Google Scholar
• CalverleyPMMartinezFJFabbriLMGoehringUMRabeKFDoes roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocolInt J Chron Obstruct Pulmon Dis2012737538222791991
   PubMed Web of Science ®Google Scholar
• KardosPMakrosIVogelmeierCEffects of roflumilast on quality of life in frequent and infrequent exacerbatorsEur Resp J201342Suppl 57P4150
   Google Scholar
• KocksJWTuinengaMGUilSMvan den BergJWStåhlEvan der MolenTHealth status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaireRespir Res200676216603063
   PubMed Web of Science ®Google Scholar
• JonesPWBrusselleGDal NegroRWProperties of the COPD assessment test in a cross-sectional European studyEur Respir J2011381293521565915
   PubMed Web of Science ®Google Scholar
• National Institutes of Health National Heart, Lung, and Blood InstituteMorbidity and Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood DiseasesBethesda, MDNational Institutes of Health2012 Available from: http://www.nhlbi.nih.gov/files/docs/research/2012_ChartBook.pdfAccessed January 23, 2015
   Google Scholar
• European Lung White BookThe Economic Burden of Lung DiseaseSheffieldEuropean Lung White Book2014 Available from: http://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease/Accessed January 23, 2015
   Google Scholar
• HertelNKotchieRWSamyshkinYRadfordMHumphreysSJamesonKCost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysisInt J Chron Obstruct Pulmon Dis2012718319922500119
   PubMed Web of Science ®Google Scholar
• SunSXMarynchenkoMBanerjeeRCost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPDJ Med Econ201114680581521992217
   PubMedGoogle Scholar
• MichalskiJMGoldenGIkariJRennardSIPDE4: a novel target in the treatment of chronic obstructive pulmonary diseaseClin Pharmacol Ther201291113414222130119
   PubMed Web of Science ®Google Scholar
• CalverleyPMAFabbriLMRabeKFMosbergHRoflumilast in the treatment of COPD: a pooled safety analysisEur Respir J201036Suppl 54 Abstract P4001
   Google Scholar
• ScholsAMSlangenJVolovicsLWoutersEFWeight loss is a reversible factor in the prognosis of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981576 Pt 1179117979620907
   PubMed Web of Science ®Google Scholar
• OmarBZmuda-TrzebiatowskaEManganielloVGöranssonODegermanERegulation of AMP-activated protein kinase by cAMP in adipocytes: roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysisCell Signal200921576076619167487
   PubMed Web of Science ®Google Scholar
• OngWKGribbleFMReimannFThe role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 releaseBr J Pharmacol2009157463364419371330
   PubMed Web of Science ®Google Scholar
• DavidsonJAIncretin-based therapies: focus on effects beyond glycemic control aloneDiabetes Ther20134222123824057947
   PubMed Web of Science ®Google Scholar
• WoutersEFBredenbrokerDTeichmannPEffect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitusJ Clin Endocrinol Metab2012979E1720E172522723325
   PubMed Web of Science ®Google Scholar
• WhiteWBCookeGEKoweyPRCardiovascular safety in patients receiving roflumilast for the treatment of COPDChest2013144375876523412642
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoASusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• CalverleyPMStockleyRASeemungalTAINSPRIE InvestigatorsReported pneumonia in patients with COPD: findings from the INSPIRE studyChest2011139350551220576732
   PubMed Web of Science ®Google Scholar
• YawnBPLiYTianHZhangJArconaSKahlerKHInhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysisInt J Chron Obstruct Pulmon Dis2013829530423836970
   PubMed Web of Science ®Google Scholar
• JansonCLarssonKLisspersKHPneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS)BMJ2013346f330623719639
   PubMed Web of Science ®Google Scholar
• YuTFainKBoydCMBenefits and harms of roflumilast in moderate to severe COPDThorax20146961662224347460
   PubMed Web of Science ®Google Scholar
• Nussbaumer-OchsnerYRabeKFSystemic manifestations of COPDChest2011139116517321208876
   PubMed Web of Science ®Google Scholar
• LangePMarottJLVestboJPrediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general populationAm J Respir Crit Care Med20121861097598122997207
   PubMed Web of Science ®Google Scholar
• BarnesNCSaettaMRabeKFImplementing lessons learned from previous bronchial biopsy trials in a new randomized controlled COPD biopsy trial with roflumilastBMC Pulmon Med2014149
   Web of Science ®Google Scholar